Investor FAQs

Investor FAQs

Show All
When was the Company founded/incorporated?

We were originally incorporated in the state of Minnesota in December 2002 and reincorporated in the state of Delaware in July 2004. In 2017, we changed our name from EnteroMedics Inc. to ReShape Lifesciences Inc.

Where are the Company offices located?

Our principal executive offices are located at:
1001 Calle Amanecer
San Clemente, CA 92673
and
5421 Avenida Encinas
Carlsbad, CA 92008
Our telephone number is (949) 429-6680.

When did the Company go public?
  • The Company completed its initial public offering for the OTC markets on November 15, 2007
  • The Company listed on The Nasdaq Capital Market on June 16, 2021
What exchange does the Company trade and what is the ticker?

ReShape Lifesciences trades on NASDAQ under the symbol RSLS.

When does the Company fiscal year end?

The Company operates with a December 31 fiscal year end.

How can I get a copy of the Company's financial statements?

Annual Reports, Form 10-Ks, Form 10-Qs and other reports are posted to this website as soon as they are filed with the SEC.

How can I buy shares of the Company?

Contact a licensed stockbroker to purchase shares in our company.

What industry is the Company in?

We are the premier global weight-loss solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and associated metabolic disease.

Does the Company pay dividends?

The Company has not historically paid dividends.

Who is the Company's transfer agent?

AST
Toll Free: (800) 937-5449
Email: help@astfinancial.com

What is a transfer agent?

A transfer agent is a trust company, bank or similar financial institution assigned by a corporation to maintain records of investors and account balances.

What is ReShape Lifesciences' CUSIP number?

76090R101

Who are ReShape Lifesciences' independent accountants?

BDO (Costa Mesa, CA)

Which state is ReShape Lifesciences incorporated?

ReShape is incorporated in Delaware

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Daniel Kontoh-Boateng
Vice President
The Ruth Group
646-536-7028/7019
dboateng@theruthgroup.com

PRINT PAGE

EMAIL PAGE